We look forward to the journey ahead with optimism. Reaching this milestone, we remain focused on flexibility, innovation and embracing new opportunities. At this vital crossroads, we will implement our transformation strategy, which includes enhanced R&D and diversification. The foundations laid by our steadfast founder now allow us to take on more complex formulation, API and DC in the core business while expanding into nutraceuticals.
We thank all of our customers, many of whom we have worked with for decades, some testament to our strong customer relations.
Sri Krishna enters this new decade firm in the belief that demand for our products will be far reaching. Further development in finished dosage and formulation will keep in touch with API diversity.
• All units integrated under one name: Sri Krishna Pharmaceuticals Limited
• USFDA, TGA and WHO GMP inspections at Unit I for Acetaminophen (Paracetamol) and Domperidone / Domperidone Maleate
• Renewed Unit II GMP compliance certificates received from German, Brazilian (ANVISA) and Mexican (COFEPRIS) regulatory authorities
• Unit II gains Italian (AIFA) approval for all solid dosage formats
• Unit III receives surveillance inspection and certification by USFDA for Folic Acid manufacturing
• USFDA inspection and TGA, AFSSAPS, WHO GMP approval for Acetaminophen (Paracetamol)
• AIFA, AFSSAPS, WHO GMP approval for Domperidone/ Domperidone Maleate
• Formulation manufacturing started, and direct compression granules roll out at Unit II
• Unit II receives TGA, AIFA GMP and ISO 9001:2008 (AQA) IN 013630 QMS compliance certification and USFDA compliance for GMP of Acetaminophen Granules DC 90%
• Acquisition of Arandy Labs in Bollaram, Hyderabad (Unit IV) – providing a niche API manufacturing facility and range of anti-diabetic products
• Solapur manufacturing facility (Unit V) established for custom synthesized intermediates
• Unit I upgraded with a focus on compliance with GMP practices
• Second facility at Nacharam (Unit II) established as a direct compression facility
• Third facility set up as Sri Krishna Drugs at Shamshabad (Unit III)
• Sri Krishna Drugs becomes the first private sector company in India to manufacture folic acid
• Sri Krishna Pharmaceuticals established in 1974 by Dr. V V Subba Reddy at Uppal, Hyderabad (Unit I)
• Production goes live for Acetaminophen (Paracetamol) at the Uppal facility